StockDriftsStockDriftsEngenbio (354200) has 5 disclosed insider purchases and 0 disclosed disposals on record, filed by 1 distinct insiders. Together those filings cover ₩99M ($68K) in reported transaction value. The earliest filing StockDrifts holds for Engenbio is dated 2024-04-09; the most recent is 2026-06-25. All of it is parsed from DART D001/D002 insider disclosures, the official disclosure system operated by the Financial Supervisory Service (Korea). Across these filings the average return since disclosure is -32.98%, measured from each filing date to the latest available close.
| Date | Type | Source | Insider | Position | Shares | Price at filing | Return | Value |
|---|---|---|---|---|---|---|---|---|
| 2026-08-14 | SELL | 장외매도 | 에스에이치헬스케어투자1호조합 SH Healthcare Investment Association No. 1 | - | -785.6K | ₩1,998 | +0.0% | ₩1.6B ($1.1M) |
| 2026-08-04 | BUY | 기타 | 에스에이치헬스케어투자1호조합 SH Healthcare Investment Association No. 1 | - | 1.6M | ₩1,747 | +4.6% | ₩2.7B ($1.9M) |
| 2026-07-29 | BUY | Market Buy | 김민식 Minsik Kim | CEO | 30.2K | ₩1,545 | +4.9% | ₩72M ($50K) |
| 2026-07-28 | BUY | Market Buy | 김민식 Minsik Kim | CEO | 12.5K | ₩1,745 | -7.1% | ₩28M ($20K) |
| 2026-06-25 | SELL | 자본감소 | 에스에이치헬스케어투자1호조합 SH Healthcare Investment Association No. 1 | - | -3.9M | - | - | - |
| 2026-06-25 | SELL | 자본감소 | 에스에이치헬스케어투자1호조합 SH Healthcare Investment Association No. 1 | - | -392.4K | ₩2,150 | +22.4% | ₩844M ($586K) |
| 2025-09-01 | SELL | 장외매도 | 홍창범 Hong Chang-beom | general manager | -6.0K | ₩1,777 | -9.2% | ₩11M ($7K) |
| 2025-09-01 | SELL | 장외매도 | 김광중 Gwangjoong Kim | Director of Research Institute | -108.0K | ₩1,777 | -9.2% | ₩192M ($133K) |
| 2025-08-01 | SELL | 장외매도 | 홍창범 Hong Chang-beom | general manager | -94.0K | ₩1,756 | -10.5% | ₩165M ($115K) |
| 2025-08-01 | SELL | 장외매도 | 최대출 maximum output | vice president | -80.0K | ₩1,756 | -10.5% | ₩140M ($98K) |
| 2025-06-28 | BUY | 신규보고 | 에스에이치헬스케어투자1호조합 SH Healthcare Investment Association No. 1 | - | 5.9M | - | - | - |
| 2025-06-28 | BUY | 신규보고 | 에스에이치헬스케어투자1호조합 SH Healthcare Investment Association No. 1 | - | 5.9M | - | - | - |
| 2024-12-20 | BUY | 유상신주취득 | 홍창범 Hong Chang-beom | general manager | 31.7K | ₩2,130 | -8.9% | ₩67M ($47K) |
| 2024-12-20 | BUY | 주식매수선택권 | 최대출 maximum output | CEO | 80.3K | ₩2,130 | -8.9% | ₩171M ($119K) |
| 2024-12-18 | BUY | 유상신주취득 | 윤세혁 Sehyuk Yoon | general manager | 15.0K | ₩2,295 | -15.4% | ₩34M ($24K) |
| 2024-12-18 | BUY | 유상신주취득 | 최대출 maximum output | CEO | 134.2K | ₩2,295 | -15.4% | ₩308M ($214K) |
| 2024-12-18 | BUY | 유상신주취득 | 김지연 Jiyeon Kim | general manager | 2.0K | ₩2,295 | -15.4% | ₩5M ($3K) |
| 2024-12-18 | BUY | 유상신주취득 | 김광중 Gwangjoong Kim | Internal director | 43.2K | ₩2,295 | -15.4% | ₩99M ($69K) |
| 2024-12-09 | SELL | 기타 | 윤세혁 Sehyuk Yoon | general manager | -11.1K | ₩2,010 | +3.4% | ₩22M ($15K) |
| 2024-12-09 | SELL | 기타 | 김지연 Jiyeon Kim | general manager | -1.7K | ₩2,010 | +3.4% | ₩3M ($2K) |
| 2024-12-09 | SELL | 기타 | 홍창범 Hong Chang-beom | general manager | -25.8K | ₩2,010 | +3.4% | ₩52M ($36K) |
| 2024-12-09 | SELL | 기타 | 김광중 Gwangjoong Kim | Internal director | -33.2K | ₩2,010 | +3.4% | ₩67M ($46K) |
| 2024-12-09 | SELL | 기타 | 최대출 maximum output | CEO | -110.7K | ₩2,010 | +3.4% | ₩223M ($155K) |
| 2024-11-20 | SELL | 장외매도 | 최대출 maximum output | CEO | -129.5K | ₩2,695 | +28.0% | ₩349M ($242K) |
| 2024-11-20 | SELL | 장외매도 | 김지연 Jiyeon Kim | general manager | -4.7K | ₩2,695 | +28.0% | ₩13M ($9K) |
| 2024-11-20 | SELL | 장외매도 | 홍창범 Hong Chang-beom | general manager | -78.0K | ₩2,695 | +28.0% | ₩210M ($146K) |
| 2024-11-20 | SELL | 장외매도 | 윤세혁 Sehyuk Yoon | general manager | -27.2K | ₩2,695 | +28.0% | ₩73M ($51K) |
| 2024-11-20 | SELL | 장외매도 | 김광중 Gwangjoong Kim | Internal director | -37.2K | ₩2,695 | +28.0% | ₩100M ($70K) |
| 2024-11-14 | BUY | 기타 | 윤세혁 Sehyuk Yoon | general manager | 38.3K | ₩2,395 | -19.0% | ₩92M ($64K) |
| 2024-11-14 | BUY | 기타 | 홍창범 Hong Chang-beom | general manager | 103.8K | ₩2,395 | -19.0% | ₩249M ($173K) |
| 2024-11-14 | BUY | 기타 | 김지연 Jiyeon Kim | general manager | 6.4K | ₩2,395 | -19.0% | ₩15M ($11K) |
| 2024-11-14 | BUY | 기타 | 최대출 maximum output | CEO | 240.2K | ₩2,395 | -19.0% | ₩575M ($400K) |
| 2024-11-14 | BUY | 기타 | 김광중 Gwangjoong Kim | Internal director | 70.4K | ₩2,395 | -19.0% | ₩169M ($117K) |
| 2024-07-17 | BUY | Market Buy | 최대출 maximum output | CEO | 1.1K | ₩2,718 | -28.6% | ₩3M ($2K) |
| 2024-07-16 | BUY | Market Buy | 최대출 maximum output | CEO | 4.7K | ₩2,709 | -28.4% | ₩13M ($9K) |
| 2024-07-15 | BUY | Market Buy | 최대출 maximum output | CEO | 5.8K | ₩2,709 | -28.4% | ₩16M ($11K) |
| 2024-07-12 | BUY | Market Buy | 최대출 maximum output | CEO | 10.0K | ₩2,695 | -28.0% | ₩27M ($19K) |
| 2024-04-30 | BUY | Market Buy | 최대출 maximum output | CEO | 10.0K | ₩4,012 | -51.6% | ₩40M ($28K) |
| 2024-04-15 | SELL | 장외매도 | 젠큐릭스 Gencurix | - | -640.0K | ₩6,214 | +68.8% | ₩4.0B ($2.8M) |
| 2024-04-09 | BUY | 장외매수 | 최대출 maximum output | CEO | 10.0K | ₩5,930 | -67.3% | ₩59M ($41K) |
| 2024-04-09 | SELL | 장외매도 | 젠큐릭스 Gencurix | - | -220.0K | ₩5,930 | +67.3% | ₩1.3B ($906K) |
| 2024-04-09 | BUY | 장외매수 | 김광중 Gwangjoong Kim | Internal director | 10.0K | ₩5,930 | -67.3% | ₩59M ($41K) |
Every trade listed above is disclosed in DART D001/D002 insider disclosures, filed with the Financial Supervisory Service (Korea). View the original DART filings for Engenbio. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse every Korean stock we track.